Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PARKINSON’S DISEASE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL PARKINSON’S DISEASE MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL PARKINSON’S DISEASE MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
2.5 GLOBAL PARKINSON’S DISEASE MARKET: RESEARCH SNAPSHOT
2.6 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATEINT TREATMENT SUCCESS RATES
7 REGULATORY SCENARIO
8 INDUSTRY INSIGHTS
8.1 PATENT ANALYSIS
8.2 DRUG TREATMENT RATE BY MATURED MARKETS
8.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
8.4 PATIENT FLOW DIAGRAM
8.5 KEY PRICING STRATEGIES
8.6 KEY PATIENT ENROLLMENT STRATEGIES
8.7 INTERVIEWS WITH HEMATOLOGISTS
8.8 INTERVIEWS WITH ONCOLOGISTS
8.9 INTERVIEWS WITH CANCER ORGANIZATIONS
8.1 OTHER KOL SNAPSHOTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 GLOBAL PARKINSON’S DISEASE MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 MEDICATION
10.2.1 DECARBOXYLASE INHIBITORS (CARBIDOPA-LEVODOPA)
10.2.2 DOPAMINE AGONISTS
10.2.2.1. PRAMIPEXOLE
10.2.2.2. ROPINIROLE
10.2.2.3. ROTIGOTINE
10.2.2.4. APOMORPHINE
10.2.2.5. OTHERS
10.2.3 MAO-B INHIBITORS
10.2.3.1. SELEGILINE
10.2.3.2. RASAGILINE
10.2.3.3. SAFINAMIDE
10.2.3.4. OTHERS
10.2.4 COMT INHIBITORS
10.2.4.1. ENTACAPONE
10.2.4.2. TOLCAPONE
10.2.4.3. OPICAPONE
10.2.4.4. OTHERS
10.2.5 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) OR SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
10.2.5.1. FLUOXETINE
10.2.5.2. VENLAFAXINE
10.2.5.3. CITALOPRAM
10.2.5.4. OTHERS
10.2.6 TRICYCLIC ANTIDEPRESSANTS
10.2.6.1. PROTRIPTYLINE
10.2.6.2. NORTRIPTYLINE
10.2.6.3. DESIPRAMINE
10.2.6.4. OTHERS
10.2.7 ANTICHOLINERGICS
10.2.7.1. BENZTROPINE
10.2.7.2. TRIHEXYPHENIDYL
10.2.7.3. OTHERS
10.3 DEVICES
10.3.1.1. DEEP BRAIN STIMULATION (DBS) DEVICES
10.3.1.1.1. EXTERNAL DBS
10.3.1.1.2. INTERNAL DBS
10.3.1.2. CARBIDOPA/LEVODOPA ENTERAL SUSPENSION (DUOPA) DELIVERY DEVICES)
10.4 OTHERS
11 GLOBAL PARKINSON’S DISEASE MARKET, BY TYPE
11.1 OVERVIEW
11.2 IDIOPATHIC PARKINSON'S
11.2.1 BY AGE GROUP
11.2.1.1. CHILD
11.2.1.2. ADULT
11.2.1.3. GERAITRIC
11.2.2 BY TREATMENT
11.2.2.1. MEDICATION
11.2.2.2. DEVICES
11.2.2.3. OTHERS
11.3 JUVENILE PARKINSON'S
11.3.1 BY AGE GROUP
11.3.1.1. CHILD
11.3.1.2. ADULT
11.3.1.3. GERAITRIC
11.3.2 BY TREATMENT
11.3.2.1. MEDICATION
11.3.2.2. DEVICES
11.3.2.3. OTHERS
11.4 DRUG-INDUCED PARKINSON’S
11.4.1 BY AGE GROUP
11.4.1.1. CHILD
11.4.1.2. ADULT
11.4.1.3. GERAITRIC
11.4.2 BY TREATMENT
11.4.2.1. MEDICATION
11.4.2.2. DEVICES
11.4.2.3. OTHERS
11.5 VASCULAR PARKINSON'S
11.5.1 BY AGE GROUP
11.5.1.1. CHILD
11.5.1.2. ADULT
11.5.1.3. GERAITRIC
11.5.2 BY TREATMENT
11.5.2.1. MEDICATION
11.5.2.2. DEVICES
11.5.2.3. OTHERS
11.6 OTHERS
11.6.1 MULTIPLE SYSTEM ATROPHY (MSA)
11.6.1.1. BY AGE GROUP
11.6.1.1.1. CHILD
11.6.1.1.2. ADULT
11.6.1.1.3. GERAITRIC
11.6.1.2. BY TREATMENT
11.6.1.2.1. MEDICATION
11.6.1.2.2. DEVICES
11.6.1.2.3. OTHERS
11.6.2 PROGRESSIVE SUPRANUCLEAR PALSY (PSP)
11.6.2.1. BY AGE GROUP
11.6.2.1.1. CHILD
11.6.2.1.2. ADULT
11.6.2.1.3. GERAITRIC
11.6.2.2. BY TREATMENT
11.6.2.3. MEDICATION
11.6.2.4. DEVICES
11.6.2.5. OTHERS
11.6.3 NORMAL PRESSURE HYDROCEPHALUS
11.6.3.1. BY AGE GROUP
11.6.3.1.1. CHILD
11.6.3.1.2. ADULT
11.6.3.1.3. GERAITRIC
11.6.3.2. BY TREATMENT
11.6.3.2.1. MEDICATION
11.6.3.2.2. DEVICES
11.6.3.2.3. OTHERS
11.6.4 VARIOUS TREMORS, INCLUDING ESSENTIAL TREMOR
11.6.4.1. BY AGE GROUP
11.6.4.1.1. CHILD
11.6.4.1.2. ADULT
11.6.4.1.3. GERAITRIC
11.6.4.2. BY TREATMENT
11.6.4.2.1. MEDICATION
11.6.4.2.2. DEVICES
11.6.4.2.3. OTHERS
12 GLOBAL PARKINSON’S DISEASE MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 BRANDED
12.2.1 CARBIDOPA / LEVODOPA
12.2.2 SINEMET
12.2.3 AZILECT
12.2.4 AMANTADINE
12.2.5 PRAMIPEXOLE
12.2.6 BENZTROPINE
12.2.7 OTHERS
12.3 GENERICS
13 GLOBAL PARKINSON’S DISEASE MARKET, BY MODE OF PRESCRIPTION
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER-THE-COUNTER
14 GLOBAL PARKINSON’S DISEASE MARKET, BY AGE GROUP
14.1 OVERVIEW
14.2 PEDIATRICS
14.3 ADULTS
14.4 GERIATRICS
15 GLOBAL PARKINSON’S DISEASE MARKET, BY DOSAGE FORM
15.1 OVERVIEW
15.2 TABLET
15.2.1 IMMEDIATE RELEASE TABLETS
15.2.2 ORAL DISINTEGRATING TABLETS
15.2.3 EXTENDED RELEASE TABLETS
15.2.4 CONTROLLED RELEASE TABLETS
15.3 CAPSULES
15.3.1 IMMEDIATE RELEASE
15.3.2 EXTENDED RELEASE
15.4 ENTERAL SUSPENSION
15.5 INHALATION
15.6 INFUSION
15.7 OTHERS
16 GLOBAL PARKINSON’S DISEASE MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.2.1 PUBLIC
16.2.2 PRIVATE
16.3 SPECIALTY CLINICS
16.4 HOME HEALTHCARE
16.5 OTHERS
17 GLOBAL PARKINSON’S DISEASE MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 HOSPITAL PHARMACY
17.3 RETAIL PHARMACY
17.4 ONLINE PHARMACY
17.5 OTHERS
18 GLOBAL PARKINSON’S DISEASE MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18.5 MERGERS & ACQUISITIONS
18.6 NEW PRODUCT DEVELOPMENT & APPROVALS
18.7 EXPANSIONS
18.8 REGULATORY CHANGES
18.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
19 GLOBAL PARKINSON’S DISEASE MARKET, BY GEOGRAPHY
19.1 GLOBAL PARKINSON’S DISEASE MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
19.1.1 NORTH AMERICA
19.1.1.1. U.S.
19.1.1.2. CANADA
19.1.1.3. MEXICO
19.1.2 EUROPE
19.1.2.1. GERMANY
19.1.2.2. FRANCE
19.1.2.3. U.K.
19.1.2.4. HUNGARY
19.1.2.5. LITHUANIA
19.1.2.6. AUSTRIA
19.1.2.7. IRELAND
19.1.2.8. NORWAY
19.1.2.9. POLAND
19.1.2.10. ITALY
19.1.2.11. SPAIN
19.1.2.12. RUSSIA
19.1.2.13. BELGIUM
19.1.2.14. TURKEY
19.1.2.15. NETHERLANDS
19.1.2.16. SWITZERLAND
19.1.2.17. REST OF EUROPE
19.1.3 ASIA-PACIFIC
19.1.3.1. JAPAN
19.1.3.2. CHINA
19.1.3.3. SOUTH KOREA
19.1.3.4. INDIA
19.1.3.5. AUSTRALIA
19.1.3.6. SINGAPORE
19.1.3.7. THAILAND
19.1.3.8. MALAYSIA
19.1.3.9. INDONESIA
19.1.3.10. PHILIPPINES
19.1.3.11. VIETNAM
19.1.3.12. REST OF ASIA-PACIFIC
19.1.4 SOUTH AMERICA
19.1.4.1. BRAZIL
19.1.4.2. ARGENTINA
19.1.4.3. PERU
19.1.4.4. REST OF SOUTH AMERICA
19.1.5 MIDDLE EAST AND AFRICA
19.1.5.1. SOUTH AFRICA
19.1.5.2. SAUDI ARABIA
19.1.5.3. UAE
19.1.5.4. EGYPT
19.1.5.5. KUWAIT
19.1.5.6. ISRAEL
19.1.5.7. REST OF MIDDLE EAST AND AFRICA
19.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
19.2.1.1.
20 GLOBAL PARKINSON’S DISEASE MARKET, SWOT AND DBMR ANALYSIS
21 GLOBAL PARKINSON’S DISEASE MARKET, COMPANY PROFILE
21.1 BAUSCH HEALTH
21.1.1 COMPANY OVERVIEW
21.1.2 REVENUE ANALYSIS
21.1.3 GEOGRAPHIC PRESENCE
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPEMENTS
21.2 TEVA PHARMACEUTICAL INDUSTRIES, INC.
21.2.1 COMPANY OVERVIEW
21.2.2 REVENUE ANALYSIS
21.2.3 GEOGRAPHIC PRESENCE
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 NOVARTIS AG
21.3.1 COMPANY OVERVIEW
21.3.2 REVENUE ANALYSIS
21.3.3 GEOGRAPHIC PRESENCE
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 GLAXOSMITHKLINE PLC
21.4.1 COMPANY OVERVIEW
21.4.2 REVENUE ANALYSIS
21.4.3 GEOGRAPHIC PRESENCE
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 ABBVIE
21.5.1 COMPANY OVERVIEW
21.5.2 REVENUE ANALYSIS
21.5.3 GEOGRAPHIC PRESENCE
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 MERCK & CO. INC.
21.6.1 COMPANY OVERVIEW
21.6.2 REVENUE ANALYSIS
21.6.3 GEOGRAPHIC PRESENCE
21.6.4 PRODUCT PORTFOLIO
21.6.5 RECENT DEVELOPMENTS
21.7 BOEHRINGER INGELHEIM
21.7.1 COMPANY OVERVIEW
21.7.2 REVENUE ANALYSIS
21.7.3 GEOGRAPHIC PRESENCE
21.7.4 PRODUCT PORTFOLIO
21.7.5 RECENT DEVELOPMENTS
21.8 H. LUNDBECK A/S
21.8.1 COMPANY OVERVIEW
21.8.2 REVENUE ANALYSIS
21.8.3 GEOGRAPHIC PRESENCE
21.8.4 PRODUCT PORTFOLIO
21.8.5 RECENT DEVELOPMENTS
21.9 WOCKHARDT
21.9.1 COMPANY OVERVIEW
21.9.2 REVENUE ANALYSIS
21.9.3 GEOGRAPHIC PRESENCE
21.9.4 PRODUCT PORTFOLIO
21.9.5 RECENT DEVELOPMENTS
21.1 UCB S.A., BELGIUM
21.10.1 COMPANY OVERVIEW
21.10.2 REVENUE ANALYSIS
21.10.3 GEOGRAPHIC PRESENCE
21.10.4 PRODUCT PORTFOLIO
21.10.5 RECENT DEVELOPMENTS
21.11 ACADIA PHARMACEUTICALS INC.
21.11.1 COMPANY OVERVIEW
21.11.2 REVENUE ANALYSIS
21.11.3 GEOGRAPHIC PRESENCE
21.11.4 PRODUCT PORTFOLIO
21.11.5 RECENT DEVELOPMENTS
21.12 DOMAIN THERAPEUTICS
21.12.1 COMPANY OVERVIEW
21.12.2 REVENUE ANALYSIS
21.12.3 GEOGRAPHIC PRESENCE
21.12.4 PRODUCT PORTFOLIO
21.12.5 RECENT DEVELOPMENTS
21.13 F. HOFFMANN-LA ROCHE LTD
21.13.1 COMPANY OVERVIEW
21.13.2 REVENUE ANALYSIS
21.13.3 GEOGRAPHIC PRESENCE
21.13.4 PRODUCT PORTFOLIO
21.13.5 RECENT DEVELOPMENTS
21.14 STADA ARZNEIMITTEL AG
21.14.1 COMPANY OVERVIEW
21.14.2 REVENUE ANALYSIS
21.14.3 GEOGRAPHIC PRESENCE
21.14.4 PRODUCT PORTFOLIO
21.14.5 RECENT DEVELOPMENTS
21.15 ORION CORPORATION
21.15.1 COMPANY OVERVIEW
21.15.2 REVENUE ANALYSIS
21.15.3 GEOGRAPHIC PRESENCE
21.15.4 PRODUCT PORTFOLIO
21.15.5 RECENT DEVELOPMENTS
21.16 CIPLA
21.16.1 COMPANY OVERVIEW
21.16.2 REVENUE ANALYSIS
21.16.3 GEOGRAPHIC PRESENCE
21.16.4 PRODUCT PORTFOLIO
21.16.5 RECENT DEVELOPMENTS
21.17 DAIICHI SANKYO COMPANY, LIMITED
21.17.1 COMPANY OVERVIEW
21.17.2 REVENUE ANALYSIS
21.17.3 GEOGRAPHIC PRESENCE
21.17.4 PRODUCT PORTFOLIO
21.17.5 RECENT DEVELOPMENTS
21.18 AUROBINDO PHARMA USA
21.18.1 COMPANY OVERVIEW
21.18.2 REVENUE ANALYSIS
21.18.3 GEOGRAPHIC PRESENCE
21.18.4 PRODUCT PORTFOLIO
21.18.5 RECENT DEVELOPMENTS
21.19 CHARTWELL PHARMACEUTICALS LLC.
21.19.1 COMPANY OVERVIEW
21.19.2 REVENUE ANALYSIS
21.19.3 GEOGRAPHIC PRESENCE
21.19.4 PRODUCT PORTFOLIO
21.19.5 RECENT DEVELOPMENTS
21.2 INDOCO REMEDIES LTD
21.20.1 COMPANY OVERVIEW
21.20.2 REVENUE ANALYSIS
21.20.3 GEOGRAPHIC PRESENCE
21.20.4 PRODUCT PORTFOLIO
21.20.5 RECENT DEVELOPMENTS
21.21 ALVOGEN
21.21.1 COMPANY OVERVIEW
21.21.2 REVENUE ANALYSIS
21.21.3 GEOGRAPHIC PRESENCE
21.21.4 PRODUCT PORTFOLIO
21.21.5 RECENT DEVELOPMENTS
21.22 ABBOTT
21.22.1 COMPANY OVERVIEW
21.22.2 REVENUE ANALYSIS
21.22.3 GEOGRAPHIC PRESENCE
21.22.4 PRODUCT PORTFOLIO
21.22.5 RECENT DEVELOPMENTS
21.23 MEDTRONIC
21.23.1 COMPANY OVERVIEW
21.23.2 REVENUE ANALYSIS
21.23.3 GEOGRAPHIC PRESENCE
21.23.4 PRODUCT PORTFOLIO
21.23.5 RECENT DEVELOPMENTS
21.24 BOSTON SCIENTIFIC CORPORATION
21.24.1 COMPANY OVERVIEW
21.24.2 REVENUE ANALYSIS
21.24.3 GEOGRAPHIC PRESENCE
21.24.4 PRODUCT PORTFOLIO
21.24.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
22 RELATED REPORTS
23 CONCLUSION
24 QUESTIONNAIRE
25 ABOUT DATA BRIDGE MARKET RESEARCH
